Why the study?
Rituximab-based immunochemotherapy is the standard first-line treatment for PMBCL, but this standard is not based on results from randomized clinical trials.
Does DA-EPOCH-R-28 improve overall survival compared to R-CHOP-21 in patients with primary mediastinal B-cell lymphoma?
Does DA-EPOCH-R-28 improve overall survival compared to R-CHOP-21 in patients with primary mediastinal B-cell lymphoma?
Retrospective analysis suggests R-CHOP-21 may be a viable alternative to DA-EPOCH-R for PMBCL, with potentially fewer low-grade cardiologic complications.
Answers are grounded in this paper and cite their sources.
R-CHOP-21 and DA-EPOCH-R yield comparable PMBCL outcomes; leaves open optimal first-line choice pending randomized trials.
BACKGROUND: The standard first-line treatment for primary mediastinal B-cell lymphoma (PMBCL) patients is rituximab-based immunochemotherapy; however, this is not due to the result of randomized clinical trials. AIMS: We retrospectively investigated 53 PMBCL patient outcomes treated either with R-CHOP-21 or DA-EPOCH-R-28. The primary endpoint was overall survival (OS). Secondary endpoints were complete remission (CR), overall response rate (ORR), progression-free survival (PFS), and treatment-related complications. RESULTS: Treatment with R-CHOP-21 resulted in a 92.0% ORR (60% CR), while DA-EPOCH-R yielded a 92.6% ORR (70.4% CR). There were no differences in the occurrence of grade 3-4 hematological adverse events, but grade 1-2 cardiologic complications (P = .003) were observed more frequently in the DA-EPOCH-R arm. Median PFS and OS were not achieved. The differences in estimated 12-month PFS in R-CHOP and DA-EPOCH-R group (87% vs 73.9%) and OS (100% vs 92%) were insignificant. Patients treated with R-CHOP-21 and autologous hematopoietic stem cell transplantation (auto-HSCT) had an improved OS (P = .03) but not PFS (P = .43) compared to those treated solely with R-CHOP-21. No differences in PFS or OS were observed between patients treated with R-CHOP-21/auto-HSCT and DA-EPOCH-R. CONCLUSION: The results of this study suggest that R-CHOP-21 may be an alternative to DA-EPOCH-R treatment for PMBCL patients.
No takes yet. Share an insight, caveat, or question.
Malenda et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: